The TGA has published the outcomes of the public consultation, which closed on 19 December, that sought views on whether the required dual-naming of certain ingredients should end on 30 April 2023. 

In relation to listed medicines, only sponsors of medicines containing 'mecobalamin (comethylcobalamin)' (a form of vitamin b12) are affected.

For new or existing sponsors of mecobalamin products, plaease see the full tech alert for more information and CMA activity in relation to this consultation.